Hybio Pharmaceutical Co.. Ltd. (300199) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hybio Pharmaceutical Co.. Ltd.

Why is Hybio Pharmaceutical Co.. Ltd. ?

With a growth in Operating Profit of 179.39%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 7 consecutive quarters
OPERATING CASH FLOW(Y) Highest at CNY 267.19 MM
ROCE(HY) Highest at 13.6%
RAW MATERIAL COST(Y) Fallen by -25.74% (YoY)

With ROE of 12.39%, it has a fair valuation with a 18.48 Price to Book Value

Over the past year, while the stock has generated a return of 37.40%, its profits have risen by 195.4% ; the PEG ratio of the company is 0.8

Consistent Returns over the last 3 years

Along with generating 37.40% returns in the last 1 year, the stock has outperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Hybio Pharmaceutical Co.. Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hybio Pharmaceutical Co.. Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Hybio Pharmaceutical Co.. Ltd.

5.18%

2.31

58.68%

China Shanghai Composite

8.25%

1.20

14.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.36%

EBIT Growth (5y)

18.11%

EBIT to Interest (avg)

-1.51

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.65

Sales to Capital Employed (avg)

0.26

Tax Ratio

41.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.28%

ROE (avg)

0.88%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

190

Industry P/E

Price to Book Value

23.56

EV to EBIT

115.47

EV to EBITDA

70.75

EV to Capital Employed

7.40

EV to Sales

20.25

PEG Ratio

0.97

Dividend Yield

ROCE (Latest)

6.41%

ROE (Latest)

12.39%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 267.19 MM

ROCE(HY)

Highest at 13.6%

RAW MATERIAL COST(Y)

Fallen by -25.74% (YoY

NET SALES(Q)

At CNY 299.15 MM has Grown at 24.04%

PRE-TAX PROFIT(Q)

Highest at CNY 89.96 MM

NET PROFIT(Q)

Highest at CNY 127.86 MM

EPS(Q)

Highest at CNY 0.14

-2What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.13 times

Here's what is working for Hybio Pharmaceutical Co.. Ltd.

Pre-Tax Profit

At CNY 89.96 MM has Grown at 444.11%

over average net sales of the previous four periods of CNY 16.53 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 127.86 MM has Grown at 1,303.62%

over average net sales of the previous four periods of CNY 9.11 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Cash Flow

Highest at CNY 267.19 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

At CNY 299.15 MM has Grown at 24.04%

over average net sales of the previous four periods of CNY 241.18 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

Highest at CNY 89.96 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 127.86 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.14

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -25.74% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hybio Pharmaceutical Co.. Ltd.

Inventory Turnover Ratio

Lowest at 1.13 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio